AU664281B2 - Novel pyrazole derivatives, method of preparing them and pharamceutical compositions in which they are present - Google Patents

Novel pyrazole derivatives, method of preparing them and pharamceutical compositions in which they are present Download PDF

Info

Publication number
AU664281B2
AU664281B2 AU41438/93A AU4143893A AU664281B2 AU 664281 B2 AU664281 B2 AU 664281B2 AU 41438/93 A AU41438/93 A AU 41438/93A AU 4143893 A AU4143893 A AU 4143893A AU 664281 B2 AU664281 B2 AU 664281B2
Authority
AU
Australia
Prior art keywords
alkyl
group
hydrogen
formula
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU41438/93A
Other versions
AU4143893A (en
Inventor
Francis Barth
Pierre Casellas
Christian Congy
Serge Martinez
Murielle Rinaldi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Elf Sanofi SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9431062&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU664281(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Elf Sanofi SA filed Critical Elf Sanofi SA
Publication of AU4143893A publication Critical patent/AU4143893A/en
Application granted granted Critical
Publication of AU664281B2 publication Critical patent/AU664281B2/en
Assigned to SANOFI reassignment SANOFI Request to Amend Deed and Register Assignors: ELF SANOFI
Assigned to SANOFI-SYNTHELABO reassignment SANOFI-SYNTHELABO Request to Amend Deed and Register Assignors: SANOFI
Assigned to SANOFI-AVENTIS reassignment SANOFI-AVENTIS Request to Amend Deed and Register Assignors: SANOFI-SYNTHELABO
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C07D231/20—One oxygen atom attached in position 3 or 5
    • C07D231/22—One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C07D231/40—Acylated on said nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

The subject of the invention is pyrazole derivatives of formula I: <IMAGE> in which - g2, g3, g4, g5, g6 and w2, w3, w4, w5 and w6 are identical or different and independently represent hydrogen, a chlorine or bromine atom, a (C1-C3)alkyl, a (C1-C3)alkoxy, a trifluoromethyl or a nitro group and g4 optionally represents a phenyl group; - R4 represents hydrogen or a (C1-C3)alkyl; - X represents either a direct bond or a group -(CH2)x-N(R3)- in which R3 represents hydrogen or a (C1-C3)alkyl and x represents zero or one; - R represents . a group -NR1R2, in which R1 and R2 independently represent a (C1-C6)alkyl group; an optionally substituted, nonaromatic (C3-C15)carbocyclic radical; an amino(C1-C4)alkyl group in which the amino is optionally disubstituted by a (C1-C3)alkyl; a cycloalkyl(C1-C3)alkyl in which the cycloalkyl is (C3-C12); a phenyl which is unsubstituted or substituted one or more times by a halogen, by a (C1-C5)alkyl or by a (C1-C5)alkoxy; a phenyl(C1-C3)alkyl; a diphenyl(C1-C3)alkyl; a naphthyl; an anthryl; a saturated, 5- to 8-membered heterocyclic radical which is unsubstituted or substituted by a (C1-C3)alkyl, hydroxyl or benzyl; a 1-adamantylmethyl; an aromatic heterocycle which is unsubstituted or substituted one or more times by a halogen, a (C1-C5)alkyl or a (C1-C5)alkoxy; a (C1-C3)alkyl which is substituted by an aromatic heterocycle which is unsubstituted or substituted one or more times by a halogen, a (C1-C5)alkyl or a (C1-C5)alkoxy; or else R1 is hydrogen and R2 is as defined above; or yet again R1 and R2 constitute, with the nitrogen atom to which they are bonded, a saturated, 5- to 8-membered heterocyclic radical, the said heterocyclic radical being other than morpholinyl when w2, w3, w4, w5, w6, g2, g3, g4, g5 and g6 are all hydrogen; . a group R2 as defined above when X represents -(CH2)xN(R3)-; . a group R5 when X represents a direct bond, R5 being represented by a (C1-C3)alkyl; a (C3-C12)cycloalkyl which is unsubstituted or substituted by a (C1-C5)alkyl; a phenyl(C1-C3)alkyl which is unsubstituted or substituted by a halogen or by a (C1-C5)alkyl; a cycloalkyl(C1-C3)alkyl in which the cycloalkyl is C3-C12 and is unsubstituted or substituted by a (C1-C5)alkyl; or a 2-norbornylmethyl; or one of their optional salts. Application: therapeutic treatment of pathological conditions where cannabis is involved.

Description

I i I ~ii _I _II~ 664281
AUSTRALIA
PATENTS ACT 1990 COMPLETE SPECIFICATION NAME OF APPLICANT(S): Elf Sanofi ADDRESS FOR SERVICE: DAVIES COLLISON CAVE Patent Attorneys 1 Little Collins Street, Melbourne, 3000.
INVENTION TITLE: Novel pyrazole derivatives, method of compositions in which they are present preparing them and pharmaceutical The following statement is a full description of this invention, including the best method of performing it known to me/us:-

Claims (13)

1. A compound of the formula R 4 X-CO-R g 5 g 6 Q N (I) 84 0 6 83 0 4 in which g2, 9 3 94, 9 5 and g 6 and w2, w 3 4 w 5 and w 6 are identical or different and are independently hydrogen, a chlorine or bromine atom, a (C 1 -C 3 )-alkyl, a (C-C3)- alkoxy, a trifluoromethyl or a nitro group and g4 is optionally a phenyl group; R 4 is hydrogen or a (C 1 -C 3 )-alkyl; X is either a direct bond or a group -(CH 2 )x-N(R 3 in which R 3 is hydrogen or a (C 1 -C 3 )-alkyl and x is zero or one; and R is a group -NR 1 R 2 in which R 1 and R 2 are independently a (C 1 -C 6 )-alkyl; an optionally- substituted non- aromatic (C 3 -C 15 carbocyclic radical, said substituent(s) being different from a substituted carbonyl group; an amino (C 1 -C 4 alkyl group in which the amino is optionally disubstituted by a (C 1 -C 3 alkyl; a cycloalkyl-(C 1 -C 3 alkyl in which the cycloalkyl is C 3 -C 12 a phenyl which is unsubstituted or monosubstituted or polysubstituted by a halogen, by a (C 1 -C 5 )-alkyl or by a (C1-CS)- alkoxy; a phenyl (C 1 -C 3 )-alkyl; a diphenyl-(C 1 -C 3 alkyl; a naphthyl; an anthracenyl; a saturated Sto 8-membered heterocyclic radical which is unsubstituted or substituted by a (C 1 -C 3 alkyl, by a hydroxyl or by a benzyl group a 1- >Nr O V 87 adamantylmethyl; an aromatic heterocycle unsubstituted) mono or-polysubstituted by a halogen, a (C 1 -C 5 )alkyl, a (C1-C 5 )-alkoxy or a (C 1 -C 3 )-alkyl substituted by an aromatic heterocycle unsubstituted or mono- or polysubstituted by a halogen, a (C 1 -C 5 alkyl, a (C 1 -C 5 )-alkoxy,or else R 1 is hydrogen and R 2 is as defined above, or else R 1 and R 2 together with the nitrogen atom to which they are bonded,form a saturated 5- to 8-membered heterocyclic radical, said heterocyclic radical being other than morpholine when w 2 w 3 w4, w 5 and w 6 and g2, 93, 94, 95 and 96 are all hydrogen; a group R 2 as defined above when X is (CH 2 )xN(R 3 or a group R 5 when X is a direct bond, R 5 being a (C 1 -C 3 )-alkyl; a (C 3 -C 12 )-cycloalkyl which is unsubstituted or substituted by a (C 1 -C 5 )-alkyl; a phenyl-(C 1 -C 3 )-alkyl which is unsubstituted or substituted by a halogen or by a (C 1 -C 5 )-alkyl; a cycloalkyl-(C 1 -C 3 )-alkyl in which the cycloalkyl iL C 3 -C 1 2 and is unsubstituted or substituted by a (C 1 -C 5 )-alkyl; or a 2-norbornylmethyl; or one of their salts, where appropriate.
2. A compound according to claim 1 of the formula RI C-N/ 8 5 8 6 R2 N N ,(Ia) 94 w2 2 3 2 W W 5 w3 w 4 in which w 2 w 3 w 4 w 5 and w 6 92, 93, 94, 95 and g 6 and R 4 are as defined for in claim 1, R 1 is hydrogen or a (C 1 -C 6 )-alkyl and R 2 is a non-aromatic r m 88 (C 3 -C 15 carbocyclic radical or a saturated 5- to 8- membered heterocyclic radical selected from 1- pyrrolidinyl, 1- piperidinyl, 1-hexahydroazepinyl, 4- morpholinyl and 4- thiomorpholinyl, or one of its salts.
3. A compound according to claim 1 of the formula X-C-R or one of its salts. (i) S4. A compound of formula according to claim 3 in which R 4 is hydrogen or a methyl group, or one of its salts.
5. A compound of formula according to claim 3 in which R 4 is hydrogen or methyl and X is a direct bond, or one of its salts.
6. A compound of formula according to claim 3 in which R 4 is hydrogen or methyl, X is a direct bond S 25 and R is a group -NR 1 R 2 in which R 1 is hydrogen or a methyl group and R 2 is a non-aromatic C 3 -C 1 carbocyclic radical or a saturated 5- to 8-membered heterocyclic radical selected from 1-pyrrolidinyl, 1- piperidinyl, 1-hexahydroazepinyl, 4-morpholinyl and 4- thiomorpholinyl, or one of its salts.
7. A compound of formula according to claim 3 in which R 4 is hydrogen or methyl, X is -(CH 2 )x-N(R 3 and R is -NR 1 R 2 x being zero or one, R 1 being hydroger, R 3 being hydrogen or a methyl group and R 2 being a phenyl which is unsubstituted or substituted by one or two halogen atoms, a (CI-C5)-alkyl group or a 89 (C 1 -C 5 alkoxy group, or a non-aromatic C 3 -C 1 carbocyclic radical, or one of its salts.
8. A compound according to claim 1 of the formula X-C-R I O N N (ii) cl w 4 in which X and R are as defined in claim 1 and w 4 is a methyl group or a methoxy group, or one of its salts.
9. A compound of formula (ii) according to claim 8 in which w 4 is methyl or methoxy, X is a direct bond and R is a group -NR 1 R 2 in which R 1 is hydrogen or a methyl group and R 2 is a non-aromatic C 3 carbocyclic radical, or one of its salts.
10. A compouid according to claim 8 in which w4 is methyl or methoxy, X is a group -(CH 2 )x-N(R 3 in which x is zero or one and R 3 is hydrogen or a methyl group, and R is a group -NR 1 R 2 in which R 1 is hydrogen and R 2 is a phenyl which is unsubstituted or substituted by V one or two halogen atoms, a (C 1 -C 5 )-alkyl group or a 25 (Cl-C 5 )-alkoxy group, or a non-aromatic C 3 -C 1 carbocyclic radical, or one of its salts. S 11. A compound according to claim 1 of formula (I) in which w2, w3, w 4 w 5 and w6, g2, g 3 g4, g 5 and g 6 and R 4 and X are as defined in claim 1 and R is a group -NR 1 R 2 in which R 1 is hydrogen or a (C 1 -C 6 )-alkyl group and R 2 is a 2- or 3-indolyl-(C 1 -C 3 )-alkyl group or a 2- or 3-indolyl group, or one of its salts. i I
12. A compound according to claim 1 of the formula (iii) in which X is as defined in claim 1, R is a group NRjR 2 in which R 1 is hydrogen or a (C 1 -C 6 )-alkyl and R 2 is a 2- or 3-indolyl-(C 1 -C 3 )-alkyl group or a 2- or 3- indolyl group, and either w 2 is hydrogen and w 4 is a methyl or methoxy group or w 2 and w 4 are a chlorine atom, or one of its salts.
13. A compound according to claim 1 of the formula X--R 0 (iv) in which X and R are as defined in claim 1 and g4 is a bromine atom or a methyl or trifluoromethyl group, or one of its salts.
14. A method of preparing the compounds of formula according to claim 1, which comprises treating a pyrazole-3-carboxylic acid derivative of the formula R4 COOH g 5 86 N
94-* NY(,I (IIa) a.. 91 in which w 2 w 3 w 4 w 5 and w 6 g2, g 3 g4, g 5 and g6 and R4 are as defined for in claim 1, or one of its activated forms, namely one of its esters or acid chlorides, either with an amine of the formula HNR 1 R 2 in which R 1 and R 2 are as defined for in claim 1, to give the amides of the formula O II R I R 4 C-N g 5 R6 2 N (Ia) 94 w6 g 3 w w4 in which w 2 w 3 w 4 w 5 and w 6 g2, g 3 g4, 35 and g 6 and R 4 R 1 and R 2 are as defined for or optionally with a primary amine R 3 NH 2 in which R 3 S' is as defined for in claim 1, to give the 20 intermediate amides of the formula SR 4 CO-NHR 3 o9 96 I 525 94 6 2 0 3 2 30 in which w 2 w 3 w4, w 5 and w 6 g2, g 3 g4, g 5 and g6 and R 4 and R 3 are as defined for to give, by reduction with a metal hydride, the intermediate amines of the formula L -1 7< 92 9 5 9 6 R 4 CH 2 NR N Q N (VI) 3 9 2 W 4 in which w 2 w 3 w 4 w 5 and w 6 92, 93, 94, 9 5 and 96 and R 4 and R,3 are as defined for which are converted to the amide or urea of the formula R 4 CH 2 -N-C-R 2 R 4 CH 2 -N-C-NH-R 2 0 95 96 IN or N QN 9 2 )0 6 2 93 0 9 3 0w 3 W4 (Ib).4 (IC) in which w 2 w 3 w4, w 5 and w 6 92, 93, 94, g 5 and 96 and R 2 R 3 and R 4 are as defined for by reaction with an acid chloride of the formula R 2 COCl or, respectively, an isocyanate of the formula R 2 in which R 2 is as defined for -or with a diphenylphosphoryl azide derivative in a basic medium, followed by an acid treatment in an alcoholic medium, to give the intermediate amine of the formula 30 NH 4 NH 9 5 9.6 ~rN 9 3 g 2 0 %V 3 U i k~ F- in which w 2 w 3 74, w 5 and w 6 g2, g 3 g4, g 5 and g6 and R 4 are as defined for which is reacted with an icid chloride R 2 COCl or an isocyanate R 2 -N=C=O to give respectively the amides and ureas of the formulae N-C-R 2 R 3 N-C-NH-R 2 II 0 in which w 2 w 3 w 4 w 5 and w 6 g2, 93, g 4 95 and g6 and R 4 are as defined for and R 3 is hydrogen, the same compounds in which R 3 is other than hydrogen being prepared from the above primary amine (VII) converted to a secondary amine of the formula R4 INHR' 3 (VIIb) in which w2, w3, W4, w 5 and w 6 g2, 9 3 94, 95 and 96 and R 4 are as defined for and R' 3 is a (C 1 -C 2 alkyl which are then reacted with an acid chloride R 2 COC1 or an isocyanate R 2 -N=C=O to give the amides and ureas of formulae (Id) and (Ie) as defined above in which R 3 is other than hydrogen, or with an organomanganous reagent R 5 MnX 1 in which R 5 is as defined for in claim 1 and X 1 is a halogen, to give the ketone derivatives of the formula ~i r i: R 4 C-R (If) the resulting compounds then being converted to one of their salts, where appropriate. A compound of the formula R4 CO 2 AIk O A C 1 ci Q or C CI (I'b) 4I4 in which R 4 is as defined in claim 1 and Alk is a (C 1 C 5 )-alkyl. 16. A pharmaceutical composition comprising a compound of formula according to any one of claims 1 to 13 as the active principle and at least one pharmaceutical excipient. 17. A pharmaceutical composition according to claim 16 in the form of a dosage unit in which the active principle is mixed with at least one pharmaceutical excipient. 18. A composition according to claim 17 containing from to 1000 mg of active principle. N)4 A .I .1 19. A compound according to claim 1, a method for the preparation thereof, or a pharmaceutical composition comprising a said compound, substantially as hereinbefore described with reference to the Examples. -'s-teps, features-enrmpos-iti ns d-o disclosed herein or referred to or indicatded in the specification and/or claisof this application, individually-o-r--clectively, and any and all combinations i-tWvo G±n. r moreofl s^-sf-f~-e-s--j-E-eer s 1 4 DATED this TWENTY THIRD day of JUNE 1993 Elf Sanofi by DAVIES COLLISON CAVE Patent Attorneys for the applicant(s) .vo. o j C 1 2ABSTRACT OF THE DISCLOSURE I The invention relates to compounds of formula R 4 X.CO-R 9 5 9 6 N 922 93 W4 4 in which 92 9 3, 94, g5 and 96 and w 2 W 3 W4, w 5 and w 6 are identical or different and are independently hydrogen, a chlorine or bromine atom, a (Cl-C 3 )-alkyl,a alkoxy, a trifluoromethyl or a nitro group and g4 is optionally a phenyl group; R 4 is hydrogen or a (Cl-C 3 )-alkyl; X is either a direct bond or a group -(CH 2 )x-N(R 3 in which R 3 is hydrogen or a (Cl-C 3 )-alkyl and x is zero or one; and -Ris -a group -NRlR 2 in which R, and R 2 are independently a (Cl-C 6 )-alkyl; an optionally- subst-ituted non- aromatic (C 3 -C 15 carbocyclic radical an amino (Cl-C 4 alkyl group in which the amino is optionally disubstituted by a alkyl; a cycloalkyl-(Cl-C 3 alkyl in which the cycloalkyl is C 3 -C 12 a phenyl which is unsubstituted or monosubstituted or polysubstituted by a halogen, by a (Cl-C 5 )-alkyl or by a (lC) alkoxy; a phenyl (Cl-C 3 )-alkyl; a diphenyl-(Cl-C 3 alkyl; a naphthyl; an anthracenyl; a saturated (to 8-membered heterocyclic radical which is unsubstituted or substituted by a (Cl-C 3 alkyl, by a hydroxyl or by a benzyl group :a 1- adamantylmethyl an aromatic heterocycle unsubstituted /mono or-polysubstituted by a halogen, a (Cl-C 5 )alkyl, a (Cl-C 5 )-alkoxy or a (Cl- C 3 )-alkyl substituted by an aromatic heterocycle unsubstituted or mono- or polyisubstituted by a halogen, a (Cl-C 5 alkyl, a (Cl-C-t)-alkoxy,or else am 2/2 R 1 is hydrogen and R 2 is as defined above, or else R 1 and R 2 together with the nitrogen atom to which they are bonded,form a saturated 5- to 8-membered heterocyclic radical, said heterocyclic radical being other than morpholine when w 2 w 3 w 4 w 5 and w 6 and g2, g 3 g4, g 5 and g 6 are all hydrogen; a group R 2 as defined above when X is (CH 2 )xN(R 3 or a group R 5 when X is a direct bond, R 5 being a (C 1 -C 3 )-alkyl; a (C 3 -C 12 )-cycloalkyl which is unsubstituted or substituted by a (C 1 -C 5 )-alkyl; a phenyl-(Cl-C3)-alkyl which is unsubstituted or substituted by a halogen or by a (C 1 -C 5 )-alkyl; a cycloalkyl-(C 1 -C 3 )-alkyl in which the cycloalkyl is C 3 -C 12 and is unsubstituted or substituted by a (C 1 -C 5 )-alkyl; or a 2-norbornylmethyl; or one of their salts, where appropriate. These compounds are useful as pharmaceuticals in the therapeutic areas in which cannabis is known to be involved. 'I
AU41438/93A 1992-06-23 1993-06-23 Novel pyrazole derivatives, method of preparing them and pharamceutical compositions in which they are present Ceased AU664281B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9207645A FR2692575B1 (en) 1992-06-23 1992-06-23 NOVEL PYRAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
FR9207645 1992-06-23

Publications (2)

Publication Number Publication Date
AU4143893A AU4143893A (en) 1994-01-06
AU664281B2 true AU664281B2 (en) 1995-11-09

Family

ID=9431062

Family Applications (1)

Application Number Title Priority Date Filing Date
AU41438/93A Ceased AU664281B2 (en) 1992-06-23 1993-06-23 Novel pyrazole derivatives, method of preparing them and pharamceutical compositions in which they are present

Country Status (26)

Country Link
US (1) US5624941A (en)
EP (1) EP0576357B1 (en)
JP (1) JP3238801B2 (en)
KR (1) KR100307050B1 (en)
AT (1) ATE149489T1 (en)
AU (1) AU664281B2 (en)
BR (2) BR9302435A (en)
CA (1) CA2098944C (en)
CZ (1) CZ289487B6 (en)
DE (1) DE69308395T2 (en)
DK (1) DK0576357T3 (en)
ES (1) ES2101258T3 (en)
FI (1) FI113169B (en)
FR (1) FR2692575B1 (en)
GR (1) GR3023535T3 (en)
HU (2) HU218797B (en)
IL (2) IL106099A (en)
MX (1) MX9303664A (en)
MY (1) MY113022A (en)
NO (1) NO302819B1 (en)
NZ (1) NZ247961A (en)
RU (1) RU2119917C1 (en)
SK (1) SK283399B6 (en)
TW (1) TW494096B (en)
UA (1) UA27728C2 (en)
ZA (1) ZA934511B (en)

Families Citing this family (364)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2713224B1 (en) * 1993-12-02 1996-03-01 Sanofi Sa Substituted N-piperidino-3-pyrazolecarboxamide.
FR2713225B1 (en) * 1993-12-02 1996-03-01 Sanofi Sa Substituted N-piperidino-3-pyrazolecarboxamide.
FR2692575B1 (en) * 1992-06-23 1995-06-30 Sanofi Elf NOVEL PYRAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
FR2714057B1 (en) * 1993-12-17 1996-03-08 Sanofi Elf New derivatives of 3-pyrazolecarboxamide, process for their preparation and pharmaceutical compositions containing them.
AU3577995A (en) * 1994-10-04 1996-04-26 Fujisawa Pharmaceutical Co., Ltd. Urea derivatives and their use as acat-inhibitors
FR2732967B1 (en) * 1995-04-11 1997-07-04 Sanofi Sa 1-PHENYLPYRAZOLE-3-CARBOXAMIDES SUBSTITUTED, ACTIVE IN NEUROTENSIN, THEIR PREPARATION, THE PHARMACEUTICAL COMPOSITIONS CONTAINING IT
FR2741621B1 (en) * 1995-11-23 1998-02-13 Sanofi Sa NOVEL PYRAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
FR2742148B1 (en) * 1995-12-08 1999-10-22 Sanofi Sa NOVEL PYRAZOLE-3-CARBOXAMIDE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
FR2758723B1 (en) * 1997-01-28 1999-04-23 Sanofi Sa USE OF CENTRAL CANNABINOID RECEPTOR ANTAGONISTS FOR THE PREPARATION OF DRUGS
DE19706903A1 (en) 1997-02-21 1998-08-27 Bayer Ag Use of known agonists of the central cannabinoid receptor CB 1
US5948777A (en) * 1997-03-18 1999-09-07 Smithkline Beecham Corporation Cannabinoid receptor agonists
FR2761266B1 (en) * 1997-03-28 1999-07-02 Sanofi Sa PHARMACEUTICAL COMPOSITION FORMED BY WET GRANULATION FOR THE ORAL ADMINISTRATION OF A DERIVATIVE OF N-PIPERIDINO-3- PYRAZOLECARBOXAMIDE, ITS SALTS AND THEIR SOLVATES
JP2002512188A (en) 1998-04-21 2002-04-23 ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ， アズ レプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ Cannabinoids as antioxidants and neuroprotective agents
CA2340445A1 (en) * 1998-05-04 1999-11-11 The University Of Connecticut Novel analgesic and immunomodulatory cannabinoids
US7897598B2 (en) 1998-06-09 2011-03-01 Alexandros Makriyannis Inhibitors of the anandamide transporter
US7589220B2 (en) 1998-06-09 2009-09-15 University Of Connecticut Inhibitors of the anandamide transporter
US7276613B1 (en) 1998-11-24 2007-10-02 University Of Connecticut Retro-anandamides, high affinity and stability cannabinoid receptor ligands
US7161016B1 (en) 1998-11-24 2007-01-09 University Of Connecticut Cannabimimetic lipid amides as useful medications
FR2789079B3 (en) * 1999-02-01 2001-03-02 Sanofi Synthelabo PYRAZOLECARBOXYLIC ACID DERIVATIVE, ITS PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME
US6566560B2 (en) 1999-03-22 2003-05-20 Immugen Pharmaceuticals, Inc. Resorcinolic compounds
BR0009200A (en) 1999-03-22 2001-12-26 Immugen Pharmaceuticals Inc Compounds and compositions for the treatment of diseases associated with immune dysfunction
CO5180550A1 (en) 1999-04-19 2002-07-30 Smithkline Beecham Corp FAB I INHIBITORS
AR024158A1 (en) 1999-06-01 2002-09-04 Smithkline Beecham Corp ANTIBACTERIAL COMPOUNDS
EP1413575B1 (en) * 1999-08-03 2006-10-11 Ortho-McNeil Pharmaceutical, Inc. Process for preparing derivatives of ¬(1,5-diaryl)pyrazol-3-yl|propanoic acid
FR2799124B1 (en) * 1999-10-01 2004-08-13 Sanofi Synthelabo USE OF ANTAGONISTS OF CENTRAL CANNABINOID RECEPTORS FOR THE PREPARATION OF DRUGS
IL148820A0 (en) * 1999-10-08 2002-09-12 Smithkline Beecham Corp Fab i inhibitors
US6762201B1 (en) 1999-10-08 2004-07-13 Affinium Pharmaceuticals, Inc. Fab I inhibitors
US6730684B1 (en) 1999-10-08 2004-05-04 Affinium Pharmaceuticals, Inc. Fab I inhibitors
ES2270874T3 (en) * 1999-10-08 2007-04-16 Affinium Pharmaceuticals, Inc. FAB INHIBITORS I.
CA2286442A1 (en) * 1999-10-15 2001-04-15 Universite De Montreal Compositions for increasing the concentration of cannabinoids as vasodilators and cardioprotectors againts ischaemia
US6900236B1 (en) 1999-10-18 2005-05-31 University Of Connecticut Cannabimimetic indole derivatives
US6943266B1 (en) 1999-10-18 2005-09-13 University Of Connecticut Bicyclic cannabinoid agonists for the cannabinoid receptor
US7393842B2 (en) * 2001-08-31 2008-07-01 University Of Connecticut Pyrazole analogs acting on cannabinoid receptors
MXPA02005100A (en) * 1999-10-18 2003-09-25 Alexipharma Inc Pyrazole derivatives as cannabinoid receptor antagonists.
US7741365B2 (en) 1999-10-18 2010-06-22 University Of Connecticut Peripheral cannabinoid receptor (CB2) selective ligands
US6995187B1 (en) 1999-10-18 2006-02-07 University Of Connecticut Peripheral cannabinoid receptor (CB2) selective ligands
US8084467B2 (en) 1999-10-18 2011-12-27 University Of Connecticut Pyrazole derivatives as cannabinoid receptor antagonists
US7119108B1 (en) 1999-10-18 2006-10-10 University Of Connecticut Pyrazole derivatives as cannabinoid receptor antagonists
FR2800375B1 (en) 1999-11-03 2004-07-23 Sanofi Synthelabo TRICYCLIC DERIVATIVES OF PYRAZOLECARBOXYLIC ACID, THEIR PREPARATION, THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
FR2800372B1 (en) 1999-11-03 2001-12-07 Sanofi Synthelabo TRICYCLIC DERIVATIVES OF 1-BENZYLPYRAZOLE-3- CARBOXYLIC ACID, THEIR PREPARATION, THE MEDICINAL PRODUCTS CONTAINING THEM
FR2804604B1 (en) * 2000-02-09 2005-05-27 Sanofi Synthelabo USE OF A CENTRAL CANNABINOID RECEPTOR ANTAGONIST FOR THE PREPARATION OF USEFUL DRUGS TO FACILITATE THE STOPPAGE OF TOBACCO CONSUMPTION
JP2004500401A (en) 2000-03-23 2004-01-08 ソルベイ・フアーマシユーチカルズ・ベー・ブイ 4,5-Dihydro-1H-pyrazole derivatives having CB1-antagonistic activity
US6492385B2 (en) 2000-08-18 2002-12-10 Pharmacia & Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease
US6500840B2 (en) 2000-08-21 2002-12-31 Pharmacia & Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease
WO2002015662A2 (en) 2000-08-21 2002-02-28 Pharmacia & Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease (nicotinic acetylcholine receptor antagonists
US20020137802A1 (en) * 2000-09-28 2002-09-26 Travis Craig R. Methods and compounds for inhibiting eicosanoid metabolism and platelet aggregation
AU2002213429A1 (en) * 2000-09-28 2002-04-08 Immugen Pharmaceuticals, Inc. Antiviral methods and compounds
US20020091114A1 (en) 2000-10-04 2002-07-11 Odile Piot-Grosjean Combination of a CB1 receptor antagonist and of sibutramine, the pharmaceutical compositions comprising them and their use in the treatment of obesity
US7329651B2 (en) 2001-01-26 2008-02-12 University Of Connecticut Cannabimimetic ligands
CA2436133A1 (en) 2001-01-29 2002-08-08 University Of Connecticut Receptor selective cannabimimetic aminoalkylindoles
US7067539B2 (en) * 2001-02-08 2006-06-27 Schering Corporation Cannabinoid receptor ligands
EP1373216B1 (en) * 2001-03-22 2004-12-15 Solvay Pharmaceuticals B.V. 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity
WO2003088897A2 (en) * 2001-04-06 2003-10-30 Affinium Pharmaceuticals, Inc. Fab i inhibitors
AU2002320430A1 (en) * 2001-07-13 2003-01-29 University Of Connecticut Novel bicyclic and tricyclic cannabinoids
AU2002319627A1 (en) 2001-07-20 2003-03-03 Merck And Co., Inc. Substituted imidazoles as cannabinoid receptor modulators
BR0211705A (en) * 2001-08-06 2004-09-28 Astrazeneca Ab A process for preparing a stable dispersion of solid particles in an aqueous medium, a stable dispersion of aqueous solid particles, a pharmaceutical composition, a method for inhibiting ostwald ripening in a dispersion of substantially water-insoluble solid particles in an aqueous medium, and , use of an inhibitor
WO2003018585A1 (en) 2001-08-24 2003-03-06 Pharmacia & Upjohn Company Substituted-heteroaryl-7-aza[2.2.1]bicycloheptanes for the treatment of disease
CA2457922A1 (en) * 2001-08-31 2003-03-13 University Of Connecticut Novel pyrazole analogs acting on cannabinoid receptors
SI1429761T1 (en) * 2001-09-21 2007-02-28 Solvay Pharm Bv Novel 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity
TWI231757B (en) 2001-09-21 2005-05-01 Solvay Pharm Bv 1H-Imidazole derivatives having CB1 agonistic, CB1 partial agonistic or CB1-antagonistic activity
HUP0402113A3 (en) * 2001-09-21 2012-05-29 Solvay Pharm Bv 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity, preparation and use thereof
PE20030547A1 (en) * 2001-09-24 2003-08-18 Bayer Corp IMIDAZOLE DERIVATIVES FOR THE TREATMENT OF OBESITY
JP2005510492A (en) 2001-10-26 2005-04-21 ユニバーシティ オブ コネチカット A new class of potent cannabis mimetic ligands
EP1442041A1 (en) * 2001-11-08 2004-08-04 PHARMACIA &amp; UPJOHN COMPANY Azabicyclic-substituted-heteroaryl compounds for the treatment of disease
FR2831883B1 (en) * 2001-11-08 2004-07-23 Sanofi Synthelabo POLYMORPHIC FORM OF RIMONABANT, PROCESS FOR PREPARING THE SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
US20040171613A1 (en) * 2001-12-27 2004-09-02 Japan Tobacco Inc. Therapeutic agent for non-immediate type allergic diseases
US20040248956A1 (en) * 2002-01-29 2004-12-09 Hagmann William K Substituted imidazoles as cannabinoid receptor modulators
US7351729B2 (en) * 2002-03-08 2008-04-01 Signal Pharmaceuticals, Llc JNK inhibitors for use in combination therapy for treating or managing proliferative disorders and cancers
ATE486842T1 (en) * 2002-03-12 2010-11-15 Merck Sharp & Dohme SUBSTITUTED AMIDES
AU2003214226A1 (en) * 2002-03-18 2003-10-08 Immugen Pharmaceuticals, Inc. Topical formulations of resorcinols and cannibinoids and methods of use
AR038966A1 (en) 2002-03-18 2005-02-02 Solvay Pharm Bv DERIVATIVES OF TIAZOL THAT HAVE ANTAGONIST, AGONIST OR PARTIAL AGONIST ACTIVITY OF CB1
US7423067B2 (en) * 2002-03-26 2008-09-09 Merck & Co., Inc. Diphenyl cyclopentyl amides as cannabinoid-1 receptor inverse agonists
EP1492784A4 (en) * 2002-03-28 2006-03-29 Merck & Co Inc Substituted 2,3-diphenyl pyridines
CA2481313A1 (en) * 2002-04-12 2003-10-23 Merck & Co., Inc. Bicyclic amides
US7105526B2 (en) 2002-06-28 2006-09-12 Banyu Pharmaceuticals Co., Ltd. Benzimidazole derivatives
NZ537003A (en) 2002-07-18 2008-03-28 Cytos Biotechnology Ag Hapten-carrier conjugates comprising virus like particles and uses thereof
GB0216700D0 (en) * 2002-07-18 2002-08-28 Astrazeneca Ab Process
ES2301833T3 (en) 2002-07-29 2008-07-01 Hoffmann La Roche DERIVATIVES OF BENZODIOXOL.
WO2004013137A1 (en) 2002-08-01 2004-02-12 Pharmacia & Upjohn Company Llc 1h-pyrazole and 1h-pyrrole-azabicyclic compounds with alfa-7 nachr activity
UY27939A1 (en) 2002-08-21 2004-03-31 Glaxo Group Ltd COMPOUNDS
JP2006511460A (en) 2002-08-23 2006-04-06 ユニバーシティ オブ コネチカット Ketocannabinoids with therapeutic indications
US7319110B2 (en) * 2002-09-19 2008-01-15 Solvay Pharmaceuticals B.V. 1H-1,2,4-triazole-3-carboxamide derivatives having cannabinoid-CB1 receptor agonistic, partial agonistic, inverse agonistic or antagonistic activity
EP1546115A4 (en) 2002-09-27 2010-08-04 Merck Sharp & Dohme Substituted pyrimidines
US20040077650A1 (en) * 2002-10-18 2004-04-22 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
US7129239B2 (en) * 2002-10-28 2006-10-31 Pfizer Inc. Purine compounds and uses thereof
DK1575951T3 (en) * 2002-12-06 2014-09-15 Debiopharm Int Sa HETEROCYCLIC COMPOUNDS, METHODS OF PRODUCING THEREOF AND THEIR USE IN THERAPY
US7247628B2 (en) * 2002-12-12 2007-07-24 Pfizer, Inc. Cannabinoid receptor ligands and uses thereof
GB0230088D0 (en) * 2002-12-24 2003-01-29 Astrazeneca Ab Therapeutic agents
GB0230087D0 (en) * 2002-12-24 2003-01-29 Astrazeneca Ab Therapeutic agents
EP1583742B1 (en) 2003-01-02 2009-12-02 F. Hoffmann-La Roche Ag Cb 1 receptour inverse agonists
KR100674769B1 (en) 2003-01-02 2007-02-28 에프. 호프만-라 로슈 아게 Novel cb 1 receptor inverse agonists
ATE374766T1 (en) 2003-01-14 2007-10-15 Arena Pharm Inc 1,2,3-TRISUBSTITUTED ARYL AND HETEROARYL DERIVATIVES AS MODULATORS OF METABOLISM FOR THE PREVENTION AND TREATMENT OF METABOLISM-RELATED DISEASES SUCH AS DIABETES OR HYPERGLYCEMIA
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
GB0302673D0 (en) * 2003-02-06 2003-03-12 Astrazeneca Ab Pharmaceutical formulations
US7329658B2 (en) * 2003-02-06 2008-02-12 Pfizer Inc Cannabinoid receptor ligands and uses thereof
GB0302672D0 (en) * 2003-02-06 2003-03-12 Astrazeneca Ab Pharmaceutical formulations
GB0302671D0 (en) * 2003-02-06 2003-03-12 Astrazeneca Ab Pharmaceutical formulations
EP1591443B1 (en) * 2003-02-07 2010-08-25 Daiichi Sankyo Company, Limited Pyrazole derivative
US7176210B2 (en) * 2003-02-10 2007-02-13 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
EP1608377B1 (en) 2003-03-17 2008-10-01 Affinium Pharmaceuticals, Inc. Pharmaceutical compositions comprising inhibitors of fab i and further antibiotics
US7145012B2 (en) * 2003-04-23 2006-12-05 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
US7141669B2 (en) * 2003-04-23 2006-11-28 Pfizer Inc. Cannabiniod receptor ligands and uses thereof
US7268133B2 (en) * 2003-04-23 2007-09-11 Pfizer, Inc. Patent Department Cannabinoid receptor ligands and uses thereof
US20040214856A1 (en) * 2003-04-23 2004-10-28 Pfizer Inc Cannabinoid receptor ligands and uses thereof
CA2524397A1 (en) * 2003-05-07 2004-11-18 Pfizer Products Inc. Cannabinoid receptor ligands and uses thereof
US20040224963A1 (en) * 2003-05-09 2004-11-11 Pfizer Inc Pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal
NZ543741A (en) * 2003-05-30 2009-10-30 Ranbaxy Lab Ltd Substituted pyrrole derivatives and their use as HMG-Co inhibitors
US7232823B2 (en) 2003-06-09 2007-06-19 Pfizer, Inc. Cannabinoid receptor ligands and uses thereof
GB0314057D0 (en) * 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
US20040259887A1 (en) * 2003-06-18 2004-12-23 Pfizer Inc Cannabinoid receptor ligands and uses thereof
US20060135523A1 (en) * 2003-06-18 2006-06-22 Astrazeneca Ab 2-substituted 5,6-diaryl-pyrazine derivatives as cb1 modulator
GB0314261D0 (en) * 2003-06-19 2003-07-23 Astrazeneca Ab Therapeutic agents
KR100809201B1 (en) 2003-06-20 2008-02-29 에프. 호프만-라 로슈 아게 2-aminobenzothiazoles as cb1 receptor inverse agonists
FR2856683A1 (en) * 2003-06-25 2004-12-31 Sanofi Synthelabo 4-CYANOPYRAZOLE-3-CARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION
AR045047A1 (en) 2003-07-11 2005-10-12 Arena Pharm Inc ARILO AND HETEROARILO DERIVATIVES TRISUSTITUIDOS AS MODULATORS OF METABOLISM AND PROFILAXIS AND TREATMENT OF DISORDERS RELATED TO THEMSELVES
CN1902177A (en) 2003-09-22 2007-01-24 万有制药株式会社 Novel piperidine derivative
FR2861992B1 (en) * 2003-11-10 2007-07-20 Sanofi Synthelabo PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION OF A PYRAZOLE-3-CARBOXAMIDE DERIVATIVE.
ES2298840T3 (en) 2003-12-08 2008-05-16 F. Hoffmann-La Roche Ag DERIVATIVES OF TIAZOL.
TW200522944A (en) 2003-12-23 2005-07-16 Lilly Co Eli CB1 modulator compounds
JP2007084437A (en) * 2003-12-26 2007-04-05 Dai Ichi Seiyaku Co Ltd Aminoalkylpyrazole derivative
FR2864958B1 (en) * 2004-01-12 2006-02-24 Sanofi Synthelabo N - [(1,5-DIPHENYL-1H-PYRAZOL-3-YL) METHYL] SULFONAMIDE DERIVATIVE, THEIR PREPARATION AND THERAPEUTIC USE THEREOF
MXPA06008391A (en) 2004-01-28 2006-08-25 Hoffmann La Roche Novel spiro-pentacyclic compounds.
US7649002B2 (en) 2004-02-04 2010-01-19 Pfizer Inc (3,5-dimethylpiperidin-1yl)(4-phenylpyrrolidin-3-yl)methanone derivatives as MCR4 agonists
TW200533657A (en) * 2004-02-17 2005-10-16 Esteve Labor Dr Substituted pyrazoline compounds, their preparation and use as medicaments
WO2005080343A2 (en) * 2004-02-20 2005-09-01 Astrazeneca Ab 3-substituted 1,5-diphenylpyrazole derivatives useful as cb1 modulators
DE602005009500D1 (en) * 2004-02-24 2008-10-16 Glaxo Group Ltd Pyridine derivatives and their use as modulators of the CB2 receptor
EP1574211A1 (en) 2004-03-09 2005-09-14 Inserm Use of antagonists of the CB1 receptor for the manufacture of a composition useful for the treatment of hepatic diseases
US7262318B2 (en) * 2004-03-10 2007-08-28 Pfizer, Inc. Substituted heteroaryl- and phenylsulfamoyl compounds
FR2867685B1 (en) * 2004-03-17 2008-05-23 Sanofi Synthelabo USE OF A PYRAZOLE DERIVATIVE FOR THE PREPARATION OF DRUGS USEFUL IN THE PREVENTION AND TREATMENT OF CHRONIC BRONCHITIS AND OBSTRUCTIVE CHRONIC BRONCHO PNEUMOPATHY
US20080255216A1 (en) 2004-03-29 2008-10-16 Aster Susan D Diaryltriazoles as Inhibitors of 11-Beta-Hydroxysteroid Dehydrogenase-1
WO2005097127A2 (en) 2004-04-02 2005-10-20 Merck & Co., Inc. Method of treating men with metabolic and anthropometric disorders
EP1735287A1 (en) * 2004-04-03 2006-12-27 Astrazeneca AB Therapeutic agents
FR2869905B1 (en) * 2004-05-10 2008-09-05 Sanofi Synthelabo PROCESS FOR PREPARING ESTER OF 1,5-DIPHENYLPYRAZOLE CARBOXYLIC ACID
CN1950361A (en) 2004-05-10 2007-04-18 霍夫曼-拉罗奇有限公司 Pyrrole or imidazole amides for treating obesity
ITMI20041033A1 (en) * 2004-05-24 2004-08-24 Neuroscienze S C A R L PHARMACEUTICAL COMPOUNDS
TW200602314A (en) * 2004-05-28 2006-01-16 Tanabe Seiyaku Co A novel pyrrolidine compound and a process for preparing the same
JP5087406B2 (en) * 2004-06-04 2012-12-05 アフィニウム ファーマシューティカルズ， インク． Therapeutic agents and methods for making and using the same
BRPI0511874A (en) * 2004-06-09 2008-01-15 Glaxo Group Ltd pyrrolopyridine derivatives
US20050288340A1 (en) * 2004-06-29 2005-12-29 Pfizer Inc Substituted heteroaryl- and phenylsulfamoyl compounds
NZ580387A (en) 2004-07-12 2011-06-30 Cadila Healthcare Ltd Tricyclic pyrazole derivatives as cannabinoid receptor modulators
US20060025448A1 (en) 2004-07-22 2006-02-02 Cadila Healthcare Limited Hair growth stimulators
EP1775293A4 (en) * 2004-08-06 2009-09-16 Daiichi Seiyaku Co Antiplatelet agent and process for producing the same
EP1797034B1 (en) 2004-08-06 2010-06-30 Merck Sharp & Dohme Corp. Sulfonyl compounds as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1
CA2578261A1 (en) * 2004-08-06 2006-02-09 Daiichi Pharmaceutical Co., Ltd. Pyrazole derivative
GB0417910D0 (en) * 2004-08-11 2004-09-15 Novartis Ag Organic compounds
CA2577060A1 (en) * 2004-08-13 2006-02-23 Amgen Inc. Substituted benzofused heterocycles
FR2875409B1 (en) * 2004-09-17 2010-05-07 Sanofi Aventis PHARMACEUTICAL COMPOSITION COMPRISING A SOLID POLYMERIC MATRIX DISPERSION COMPRISING A CONTINUOUS PHASE OF POLYDEXTROSE AND A CONTINUOUS PHASE OF A POLYMER OTHER THAN POLYDEXTROSE
CA2581596A1 (en) * 2004-09-29 2006-04-13 Schering Corporation Combinations of substituted azetidonones and cb1 antagonists
BRPI0517369A (en) 2004-10-27 2008-10-07 Hoffmann La Roche compounds, process for their manufacture, compositions comprising them, method for the treatment and / or prophylaxis of diseases that are associated with modulation of cb1 receptors and their use
BRPI0518241A (en) 2004-11-01 2008-04-22 Amylin Pharmaceuticals Inc Methods to Treat Obesity and Obesity-Related Diseases and Disorders
US8394765B2 (en) * 2004-11-01 2013-03-12 Amylin Pharmaceuticals Llc Methods of treating obesity with two different anti-obesity agents
EP1812418B1 (en) 2004-11-09 2010-10-27 F. Hoffmann-La Roche AG Dibenzosuberone derivatives
ES2435790T3 (en) 2004-12-03 2013-12-23 Intervet International B.V. Substituted piperazines as CB1 antagonists
WO2006067443A1 (en) * 2004-12-23 2006-06-29 Astrazeneca Ab Therapeutic agents
EP1833802A2 (en) * 2004-12-23 2007-09-19 AstraZeneca AB 1,2-diphenyl-imidazole derivatives and their use as cb1 receptor ligands
FR2880023B1 (en) * 2004-12-23 2007-02-23 Sanofi Aventis Sa N - [(4,5-DIPHENYL-3-ALKYL-2-THIENYL) METHYL] AMINE DERIVATIVES AND THEIR PREPARATION AND THERAPEUTIC USE
EP1844017A1 (en) * 2005-01-06 2007-10-17 Cadila Healthcare Ltd. An amorphous and three crystalline forms of rimonabant hydrochloride
DOP2006000010A (en) 2005-01-10 2006-07-31 Arena Pharm Inc PROCEDURE TO PREPARE AROMATIC ETERES
US8853205B2 (en) 2005-01-10 2014-10-07 University Of Connecticut Heteropyrrole analogs acting on cannabinoid receptors
US8084451B2 (en) * 2005-01-10 2011-12-27 University Of Connecticut Heteropyrrole analogs acting on cannabinoid receptors
FR2880890B1 (en) * 2005-01-19 2007-03-30 Sanofi Aventis Sa N - [(4,5-DIPHENYL-2-THIENYL) METHYL] SULFONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE
PA8660701A1 (en) 2005-02-04 2006-09-22 Pfizer Prod Inc SMALL AGONISTS AND THEIR USES
FR2881744B1 (en) * 2005-02-09 2007-04-27 Sanofi Aventis Sa N - [(4,5-DIPHENYL-2-THIENYL) METHYL] AMINE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE
FR2882054B1 (en) * 2005-02-17 2007-04-13 Sanofi Aventis Sa 1,5-DIARYLPYRROLE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION
FR2882263B1 (en) * 2005-02-23 2007-04-06 Sanofi Aventis Sa USE OF A PYRAZOLE DERIVATIVE FOR THE PREPARATION OF MEDICAMENTS USEFUL IN THE PREVENTION AND TREATMENT OF RENAL DISEASES
FR2882931B1 (en) * 2005-03-14 2007-05-18 Sanofi Aventis Sa PHARMACEUTICAL COMPOSITIONS CONTAINING IN ASSOCIATION AN ANTAGONIST COMPOUND OF CANNABINOIDESS RECEPTORS AND AN ANTIPSYCHOTIC AGENT
MX2007012213A (en) 2005-04-06 2007-12-10 Hoffmann La Roche Pyridine-3-carboxamide derivatives as cb1 inverse agonists.
US7737155B2 (en) 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
JP2008542255A (en) * 2005-05-27 2008-11-27 ファイザー・プロダクツ・インク Combination of cannabinoid-1 receptor antagonist and microsomal triglyceride transfer protein inhibitor for the treatment of obesity or maintenance of weight loss
BRPI0610580B8 (en) 2005-05-30 2021-05-25 Banyu Pharma Co Ltd piperidine derivative compound
US7923465B2 (en) 2005-06-02 2011-04-12 Glenmark Pharmaceuticals S.A. Cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation
BRPI0612125A2 (en) * 2005-06-22 2010-10-19 Hoffmann La Roche compounds of formula (i), process for their manufacture, compound of formula iiia, pharmaceutical compositions, method for treatment and / or prophylaxis of diseases associated with cb1 receptor modulation and use of compounds
FR2887550A1 (en) * 2005-06-24 2006-12-29 Sanofi Aventis Sa New 1-benzylpyrazole-3-acetamide compounds are cannabinoids receptor antagonists useful to treat/prevent immune disorders, pain, gastrointestinal disturbances, cardiovascular/kidney disorders and in cancer chemotherapy
FR2887548B1 (en) * 2005-06-27 2007-09-21 Sanofi Aventis Sa 4,5-DIARYLPYRROLE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF
BRPI0613505A2 (en) 2005-06-30 2011-01-11 Prosidion Ltd gpcr agonists
JP2009500439A (en) * 2005-07-11 2009-01-08 ナームローゼ・フエンノートチヤツプ・オルガノン Synergistic combination for the treatment of pain (cannabinoid receptor agonist and opioid receptor agonist)
EP1743892A1 (en) * 2005-07-15 2007-01-17 Laboratorios del Dr. Esteve S.A. Substituted pyrazoline compounds, their preparation and use as medicaments
EP1757588A1 (en) * 2005-07-29 2007-02-28 Laboratorios Del Dr. Esteve, S.A. Polymorph of N-Piperidinyl-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4,5-dihydro-1H-pyrazole-3-carboxamide and its use as a cannabinoid receptor modulator
EP1743636A1 (en) * 2005-07-15 2007-01-17 Laboratorios Del Dr. Esteve, S.A. Combination of a substituted pyrazoline compound and a drug used in food-related disorders
ES2337005B1 (en) * 2005-07-15 2011-01-10 Laboratorios Del Dr. Esteve, S.A. COMPOUNDS OF PIRAZOLINA AZEPAN OR AZOCANSUSTITUIDOS, ITS PREPARATION AND ITS USE AS MEDICINES.
EP1743637A1 (en) 2005-07-15 2007-01-17 Laboratorios Del Dr. Esteve, S.A. Use of substituted pyrazole compounds and combinations thereof for the treatment of the metabolic syndrome
EP1743890A1 (en) * 2005-07-15 2007-01-17 Laboratorios Del Dr. Esteve, S.A. 4,5-Dihydro-1H-pyrazole derivatives, their preparation and use as medicaments
WO2007009720A2 (en) * 2005-07-15 2007-01-25 Laboratorios Del Dr. Esteve S.A. Prodrugs of pyrazoline compounds, their preparation and use as medicaments
WO2007009693A1 (en) * 2005-07-15 2007-01-25 Laboratorios Del Dr.Esteve, S.A Combination of a substituted pyrazoline compound and a drug used in food-related disorders
GB0514739D0 (en) * 2005-07-19 2005-08-24 Astrazeneca Ab Therapeutic agents
GB0514738D0 (en) * 2005-07-19 2005-08-24 Astrazeneca Ab Therapeutic agents
EP1752149A1 (en) 2005-07-29 2007-02-14 Laboratorios Del Dr. Esteve, S.A. CB1 Antagonists or inverse agonists as therapeutical agents for the treatment of inflammation involving gene expression
WO2007017126A2 (en) * 2005-07-29 2007-02-15 Laboratorios Del Dr. Esteve, S.A. POLYMORPH OF N-PIPERIDINYL-5- (4-CHLOROPHENYL) -1- (2, 4-DICHLOROPHENYL) -4, 5-DIHYDRO-lH-PYRAZOLE- 3 -CARBOXAMIDE AND ITS USE AS A CAMNABINOID RECEPTOR MODULATOR
JP2009503050A (en) * 2005-08-04 2009-01-29 ファイザー・リミテッド Piperidinoyl-pyrrolidine and piperidinoyl-piperidine compounds
CA2518579A1 (en) * 2005-08-05 2007-02-05 University Technologies International Inc. Method for appetite suppression
CA2618165A1 (en) * 2005-08-09 2007-02-15 Glaxo Group Limited Imidazopyridine derivatives as cannabinoid receptor ligands
AU2006277253A1 (en) 2005-08-10 2007-02-15 Msd K.K. Pyridone compound
BRPI0614649A2 (en) 2005-08-11 2011-04-12 Amylin Pharmaceuticals Inc hybrid polypeptides with selectable properties
AU2006279680B2 (en) 2005-08-11 2012-12-06 Amylin Pharmaceuticals, Llc Hybrid polypeptides with selectable properties
EP1915131A4 (en) * 2005-08-12 2012-07-25 Astrazeneca Ab Process
EP1757290A1 (en) * 2005-08-16 2007-02-28 Zentaris GmbH Novel triazole derivatives as ghrelin analogue ligands of growth hormone secretagogue receptors
AU2006282260A1 (en) 2005-08-24 2007-03-01 Msd K.K. Phenylpyridone derivative
JPWO2007029847A1 (en) 2005-09-07 2009-03-19 萬有製薬株式会社 Bicyclic aromatic substituted pyridone derivatives
GB0518819D0 (en) * 2005-09-15 2005-10-26 Astrazeneca Ab Therapeutic agents
CA2623803A1 (en) * 2005-09-23 2007-03-29 Janssen Pharmaceutica N.V. Tetrahydro-cyclopentyl pyrazole cannabinoid modulators
AU2006297443B2 (en) 2005-09-29 2010-08-12 Merck Sharp & Dohme Corp. Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
US7829586B2 (en) * 2005-09-30 2010-11-09 Banyu Pharmaceutical Co., Ltd. Aryl-substituted nitrogen-containing heterocyclic compounds
AR056560A1 (en) * 2005-10-06 2007-10-10 Astrazeneca Ab PIRROLOPIRIDINONES AS MODULATORS CB1
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
WO2007049798A1 (en) 2005-10-27 2007-05-03 Banyu Pharmaceutical Co., Ltd. Novel benzoxathiin derivative
US8026377B2 (en) * 2005-11-08 2011-09-27 Ranbaxy Laboratories, Limited Process for (3R, 5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid hemi calcium salt
NZ568292A (en) 2005-11-10 2011-08-26 Msd Kk Spiro[cyclohexane-1,1'-(3'H)-4'-azaisobenzofuran]-4-carboxamide derivatives
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
JP2009518399A (en) * 2005-12-05 2009-05-07 アフィニウム ファーマシューティカルズ， インク． Heterocyclic acrylamide compounds as FABI inhibitors and antibacterial agents
FR2894579B1 (en) * 2005-12-12 2008-01-18 Sanofi Aventis Sa DIARYLTRIAZOLMETHYLAMINE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE.
FR2894578B1 (en) * 2005-12-12 2008-02-01 Sanofi Aventis Sa HETEROCYCLIC DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE.
EP1801098A1 (en) 2005-12-16 2007-06-27 Merck Sante 2-Adamantylurea derivatives as selective 11B-HSD1 inhibitors
CN100999517B (en) * 2006-01-11 2010-12-15 北京摩力克科技有限公司 Pyrazole formylamine derivate, its pharmaceutical composition and preparation process
CA2637565A1 (en) 2006-01-18 2007-07-26 Schering Corporation Cannibinoid receptor modulators
WO2007096763A2 (en) * 2006-02-23 2007-08-30 Pfizer Limited Melanocortin type 4 receptor agonist piperidinoylpyrrolidines
AU2007226673A1 (en) * 2006-03-10 2007-09-20 Jenrin Discovery Cannabinoid receptor antagonists/inverse agonists useful for treating obesity
AR059838A1 (en) * 2006-03-14 2008-04-30 Ranbaxy Lab Ltd FORMULATIONS FOR STABILIZING DOSES OF STATIN
WO2007121466A2 (en) * 2006-04-18 2007-10-25 Dr. Reddy's Laboratories Ltd. Process for preparing rimonabant
US20070287734A1 (en) * 2006-06-09 2007-12-13 Auspex Pharmaceuticals, Inc. Preparation and utility of substituted pyrazole compounds with cannabinoid receptor activity
US7629346B2 (en) 2006-06-19 2009-12-08 Hoffmann-La Roche Inc. Pyrazinecarboxamide derivatives as CB1 antagonists
WO2008038143A2 (en) * 2006-06-22 2008-04-03 Medichem, S.A. Novel solid forms of rimonabant and synthetic processes for their preparation
US7803799B2 (en) * 2006-07-07 2010-09-28 National Health Research Institutes Selenophene compounds
DE602006014532D1 (en) * 2006-07-11 2010-07-08 Sanofi Aventis N-Ä (1,5-diphenyl-1H-pyrazol-3-yl) methyl-sulfonamide derivatives Antagonists of the CB1 receptors of cannabinoids
WO2008010087A2 (en) * 2006-07-14 2008-01-24 Ranbaxy Laboratories Limited Polymorphic forms of an hmg-coa reductase inhibitor and uses thereof
WO2008009122A1 (en) 2006-07-20 2008-01-24 Affinium Pharmaceuticals, Inc. Acrylamide derivatives as fab i inhibitors
EP2057144A4 (en) * 2006-09-01 2010-06-02 Hetero Drugs Ltd Novel polymorphs of rimonabant
US20100179131A1 (en) 2006-09-07 2010-07-15 Nycomed Gmbh Combination treatment for diabetes mellitus
EP2061783A2 (en) * 2006-09-11 2009-05-27 Hetero Drugs Limited Improved process for rimonabant
US7781593B2 (en) 2006-09-14 2010-08-24 Hoffmann-La Roche Inc. 5-phenyl-nicotinamide derivatives
WO2008035023A1 (en) * 2006-09-19 2008-03-27 Cipla Limited Polymorphs of rimonabant
EP2083831B1 (en) 2006-09-22 2013-12-25 Merck Sharp & Dohme Corp. Method of treatment using fatty acid synthesis inhibitors
JPWO2008038692A1 (en) 2006-09-28 2010-01-28 萬有製薬株式会社 Diaryl ketimine derivatives
TWI408136B (en) * 2006-10-02 2013-09-11 Nat Health Research Institutes Thiophene compounds and pharmaceutical composition using the same
TWI339205B (en) * 2006-10-02 2011-03-21 Nat Health Research Institutes Pyrazole compounds and pharmaceutical composition
WO2008063847A2 (en) * 2006-11-03 2008-05-29 Forest Laboratories Holdings Limited Method for treating autism
AU2007320906A1 (en) 2006-11-13 2008-05-22 Pfizer Products Inc. Diaryl, dipyridinyl and aryl-pyridinyl derivatives and uses thereof
FR2909090B1 (en) 2006-11-23 2009-01-09 Sanofi Aventis Sa SUBSTITUTED 2,5-DIHYDRO-3H-PYRAZOLO [4,3-C] PYRIDAZIN-3-ONE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE.
WO2008062480A2 (en) * 2006-11-24 2008-05-29 Ind-Swift Laboratories Limited An improved process for the preparation of rimonabant
ATE547394T1 (en) 2006-12-01 2012-03-15 Bristol Myers Squibb Co N-((3-BENZYL)-2,2-(BIS-PHENYL)-PROPANE-1- AMINE DERIVATIVES AS CETP INHIBITORS FOR THE TREATMENT OF ATHEROSCLERosis AND CARDIOVASCULAR DISEASES
CA2673359A1 (en) * 2006-12-18 2008-06-26 7Tm Pharma A/S Cb1 receptor modulators
EP1935420A1 (en) 2006-12-21 2008-06-25 Merck Sante 2-Adamantyl-butyramide derivatives as selective 11beta-HSD1 inhibitors
AR064736A1 (en) 2007-01-04 2009-04-22 Prosidion Ltd GPCR AGONISTS
WO2008081208A1 (en) 2007-01-04 2008-07-10 Prosidion Limited Piperidine gpcr agonists
DK2114933T3 (en) 2007-01-04 2012-01-02 Prosidion Ltd Piperidine GPCR agonists
AR064735A1 (en) 2007-01-04 2009-04-22 Prosidion Ltd GPCR AGONISTS AND PHARMACEUTICAL COMPOSITION BASED ON THE COMPOUND
GB0700122D0 (en) 2007-01-04 2007-02-14 Prosidion Ltd GPCR agonists
FR2911136B1 (en) * 2007-01-05 2009-02-20 Sanofi Aventis Sa SUBSTITUTED N- (4-CYANO-1H-PYRAZOL-3-YL) METHYLAMINE DERIVATIVES AND THEIR PREPARATION AND THERAPEUTIC USE THEREOF
US20080182877A1 (en) * 2007-01-05 2008-07-31 Westheim Raymond J H Rimonabant forms and methods of making the same
WO2008088900A2 (en) * 2007-01-18 2008-07-24 Teva Pharmaceutical Industries Ltd. Polymorphic forms of rimonabant base and processes for preparation thereof
TW200848039A (en) * 2007-02-09 2008-12-16 Astrazeneca Ab Pharmaceutical compositions
GB0702862D0 (en) * 2007-02-14 2007-03-28 Univ Aberdeen Therapeutic compounds
WO2008098374A1 (en) 2007-02-16 2008-08-21 Affinium Pharmaceuticals, Inc. Salts, prodrugs and polymorphs of fab i inhibitors
US20080221057A1 (en) * 2007-02-16 2008-09-11 Wyeth Secreted protein ccdc80 regulates adipocyte differentiation
WO2008102367A1 (en) * 2007-02-19 2008-08-28 Darmesh Mahendrabhai Shah Process for preparation of pyrazole derivatives
WO2008101860A1 (en) * 2007-02-20 2008-08-28 Sandoz Ag Novel process for the preparation of 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-n-(piperidin-1-yl)pyrazole-3-carboxamide
AU2008233662B2 (en) 2007-04-02 2012-08-23 Msd K.K. Indoledione derivative
US7705024B2 (en) * 2007-04-12 2010-04-27 National Health Research Institutes Oxadiazole compounds
WO2008130616A2 (en) * 2007-04-19 2008-10-30 Schering Corporation Diaryl morpholines as cb1 modulators
CN101314591B (en) * 2007-05-30 2010-09-29 上海阳帆医药科技有限公司 Novel pyrazoles highly-selective marijuana acceptor-1antagon and/or reversed activation agent
CN101742906A (en) 2007-06-04 2010-06-16 本古里安大学内盖夫研究发展局 Tri-aryl compounds and compositions comprising the same
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
EA020466B1 (en) 2007-06-04 2014-11-28 Синерджи Фармасьютикалз Инк. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
PL2167498T3 (en) * 2007-06-15 2011-03-31 Irm Llc Compounds and compositions as itpkb inhibitors
JP2010531874A (en) * 2007-06-28 2010-09-30 インターベット インターナショナル ベー． フェー． Substituted piperazines as CB1 antagonists
BRPI0814806A2 (en) * 2007-06-28 2015-02-03 Intervet Int Bv PIRAZINS REPLACED AS CB1 ANTAGONISTS
US8338623B2 (en) * 2007-07-09 2012-12-25 Abbvie Inc. Compounds as cannabinoid receptor ligands
FR2919184A1 (en) * 2007-07-26 2009-01-30 Sanofi Aventis Sa Use of 5-(4-chlorophennyl)-1-(2,4-dichlorophenyl)-4-methylpyrazole-3-carboxylic acid as a medicament for treating e.g. chronic pain, neuropathic pain, inflammation, benign hypertrophy of the prostate and diabetic neuropathy
WO2009018389A1 (en) * 2007-07-30 2009-02-05 Alltranz Inc. Prodrugs of cannabidiol, compositions comprising prodrugs of cannabidiol and methods of using the same
US8133904B2 (en) * 2007-09-07 2012-03-13 Jenrin Discovery, Inc. Cannabinoid receptor antagonists/inverse agonists useful for treating obesity
WO2009063495A2 (en) * 2007-09-20 2009-05-22 Cadila Healthcare Limited Substituted indole and its derivatives as cannabinoid modulators
GB0720389D0 (en) 2007-10-18 2008-11-12 Prosidion Ltd G-Protein Coupled Receptor Agonists
GB0720390D0 (en) 2007-10-18 2007-11-28 Prosidion Ltd G-Protein coupled receptor agonists
CN101939022A (en) * 2007-11-14 2011-01-05 安米林药品公司 Methods for treating obesity and obesity related diseases and disorders
EP2254601B1 (en) 2008-02-08 2019-05-29 Nektar Therapeutics Oligomer-cannabinoid conjugates
AU2009220605A1 (en) 2008-03-06 2009-09-11 Msd K.K. Alkylaminopyridine derivative
US20090247619A1 (en) * 2008-03-06 2009-10-01 University Of Kentucky Cannabinoid-Containing Compositions and Methods for Their Use
DE102008015032A1 (en) 2008-03-17 2009-09-24 Aicuris Gmbh & Co. Kg Substituted pyrazolamides and their use
DE102008015033A1 (en) 2008-03-17 2009-09-24 Aicuris Gmbh & Co. Kg Substituted (pyrazolyl-carbonyl) imidazolidinones and their use
EP2103602A1 (en) 2008-03-17 2009-09-23 AEterna Zentaris GmbH Novel 1,2,4-triazole derivatives and process of manufacturing thereof
AU2009229860A1 (en) 2008-03-28 2009-10-01 Msd K.K. Diarylmethylamide derivative having antagonistic activity on melanin-concentrating hormone receptor
EP2110374A1 (en) 2008-04-18 2009-10-21 Merck Sante Benzofurane, benzothiophene, benzothiazol derivatives as FXR modulators
EP2810951B1 (en) 2008-06-04 2017-03-15 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US20110071129A1 (en) 2008-06-19 2011-03-24 Makoto Ando Spirodiamine-diaryl ketoxime derivative
ES2624828T3 (en) 2008-07-16 2017-07-17 Synergy Pharmaceuticals Inc. Guanylate cyclase agonists useful for the treatment of gastrointestinal disorders, inflammation, cancer and others
EP2151234A1 (en) * 2008-07-28 2010-02-10 Laboratorios Del. Dr. Esteve, S.A. Pharmaceutical formulation comprising a CB1-receptor compound in a solid solution and/or solid dispersion
JPWO2010013595A1 (en) 2008-07-30 2012-01-12 Ｍｓｄ株式会社 5-membered or 5-membered or 6-membered condensed cycloalkylamine derivative
DK2326638T5 (en) * 2008-08-06 2014-01-13 Pfizer Ltd DIAZEPIN AND DIAZOCAN COMPOUNDS AS MC4 AGONISTS
WO2010047982A1 (en) 2008-10-22 2010-04-29 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
PE20110852A1 (en) 2008-10-30 2011-11-25 Merck Sharp & Dohme ISONICOTINAMIDE OREXIN RECEPTOR ANTAGONISTS
CA2741672A1 (en) 2008-10-31 2010-05-06 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
TWI434686B (en) * 2008-11-03 2014-04-21 Nat Health Research Institutes Imidazol-4-one and imidazole-4-thione compounds
EP2358200A4 (en) 2008-11-17 2012-05-16 Merck Sharp & Dohme Substituted bicyclic amines for the treatment of diabetes
WO2010075068A1 (en) 2008-12-16 2010-07-01 Schering Corporation Pyridopyrimidine derivatives and methods of use thereof
EP2379562A1 (en) 2008-12-16 2011-10-26 Schering Corporation Bicyclic pyranone derivatives as nicotinic acid receptor agonists
DE102008062878A1 (en) 2008-12-17 2010-06-24 Aicuris Gmbh & Co. Kg Substituted furancarboxamides and their use
DE102008062863A1 (en) 2008-12-17 2010-06-24 Aicuris Gmbh & Co. Kg Substituted (thiophenyl-carbonyl) imidazolidinones and their use
WO2010079241A1 (en) 2009-01-12 2010-07-15 Fundacion Hospital Nacional De Paraplejicos Para La Investigacion Y La Integracion Use of antagonists and/or inverse agonists of cb1 receptors for the preparation of drugs that increase motor neuron excitability
KR101070176B1 (en) * 2009-01-13 2011-10-05 (주)에스에이치제약 1H-pyrazole-3-amide derivatives having CB1-antagonistic activity and pharmaceutical composition comprising the same
EP2395987A1 (en) 2009-02-12 2011-12-21 Coöperatieve Mirzorg U.A., Arnhem Use of a combination of diazoxide and metformin for treating obesity or obesity related disorders
US10053444B2 (en) 2009-02-19 2018-08-21 University Of Connecticut Cannabinergic nitrate esters and related analogs
US20120220567A1 (en) 2009-07-23 2012-08-30 Shipps Jr Gerald W Benzo-fused oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors
WO2011011506A1 (en) 2009-07-23 2011-01-27 Schering Corporation Spirocyclic oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors
DE102009036604A1 (en) 2009-07-30 2011-02-03 Aicuris Gmbh & Co. Kg Substituted bis-arylpyrazolamides with terminal primary amide functionality and their use
US8217038B2 (en) 2009-10-07 2012-07-10 Jenrin Discovery, Inc. Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes
ES2527179T3 (en) 2009-11-02 2015-01-21 Pfizer Inc. Dioxa-bicyclo derivatives [3.2.1] octane-2,3,4-triol
CA2779088A1 (en) 2009-11-16 2011-05-19 Mellitech [1,5]-diazocin derivatives
CA2784799C (en) 2009-12-30 2014-06-10 Shanghai Fochon Pharmaceutical Co Ltd Certain dipeptidyl peptidase inhibtors
JP5856980B2 (en) 2010-01-27 2016-02-10 アリーナ ファーマシューティカルズ， インコーポレイテッド (R) -2- (7- (4-Cyclopentyl-3- (trifluoromethyl) benzyloxy) -1,2,3,4-tetrahydrocyclopenta [b] indol-3-yl) acetic acid and its salts Process for preparation
AU2011218830B2 (en) 2010-02-25 2014-07-24 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
WO2011137024A1 (en) 2010-04-26 2011-11-03 Merck Sharp & Dohme Corp. Novel spiropiperidine prolylcarboxypeptidase inhibitors
CA2798831A1 (en) 2010-05-11 2011-11-17 Pfizer Inc. Morpholine compounds as mineralocorticoid receptor antagonists
US9365539B2 (en) 2010-05-11 2016-06-14 Merck Sharp & Dohme Corp. Prolylcarboxypeptidase inhibitors
US9006268B2 (en) 2010-06-11 2015-04-14 Merck Sharp & Dohme Corp. Prolylcarboxypeptidase inhibitors
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
EP2431035A1 (en) 2010-09-16 2012-03-21 Æterna Zentaris GmbH Novel Triazole Derivatives with Improved Receptor Activity and Bioavailability Properties as Ghrelin Antagonists of Growth Hormone Secretagogue Receptors
CA2812061A1 (en) 2010-09-22 2012-03-29 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
US8410107B2 (en) 2010-10-15 2013-04-02 Hoffmann-La Roche Inc. N-pyridin-3-yl or N-pyrazin-2-yl carboxamides
US8669254B2 (en) 2010-12-15 2014-03-11 Hoffman-La Roche Inc. Pyridine, pyridazine, pyrimidine or pyrazine carboxamides as HDL-cholesterol raising agents
EP3243385B1 (en) 2011-02-25 2021-01-13 Merck Sharp & Dohme Corp. Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
CN102206182B (en) * 2011-04-11 2013-03-13 中国药科大学 Method for synthesizing Rimonabant hydrochloride
CN102250006B (en) * 2011-05-12 2014-03-05 范如霖 3-pyrazole carboxylic acid amide compounds, preparation method thereof and application thereof in preparation of medicament serving as CB1 receptor inhibitor
WO2012174362A1 (en) 2011-06-17 2012-12-20 Research Triangle Institute Pyrazole derivatives as cannabinoid receptor 1 antagonists
AR087701A1 (en) 2011-08-31 2014-04-09 Japan Tobacco Inc PIRAZOL DERIVATIVES WITH SGLT1 INHIBITING ACTIVITY
WO2013041602A1 (en) 2011-09-23 2013-03-28 Bayer Intellectual Property Gmbh Use of 4-substituted 1-phenyl-pyrazole-3-carboxylic-acid derivatives as agents against abiotic plant stress
AR088352A1 (en) 2011-10-19 2014-05-28 Merck Sharp & Dohme ANTAGONISTS OF THE RECEIVER OF 2-PIRIDILOXI-4-NITRILE OREXINE
DE102011055815A1 (en) 2011-11-29 2013-05-29 Aicuris Gmbh & Co. Kg Carboxamide-substituted heteroaryl-pyrazoles and their use
AR089656A1 (en) * 2011-11-30 2014-09-10 Bayer Ip Gmbh DERIVATIVES OF N-BICICLOALQUIL- AND N-TRICICLOALQUIL- (TIO) -CARBOXAMIDA FUNGICIDAS
DK2861608T3 (en) 2012-06-19 2019-06-24 Debiopharm Int Sa PRODRUG DERIVATIVES OF (E) -N-METHYL-N - ((3-METHYLBENZOPHURAN-2-YL) METHYL) -3- (7-OXO-5,6,7,8-TETRAHYDRO-1,8-NAPHTHYRIDIN) 3-yl) -acrylamide
JP2015525782A (en) 2012-08-02 2015-09-07 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Antidiabetic tricyclic compounds
DE102012016908A1 (en) 2012-08-17 2014-02-20 Aicuris Gmbh & Co. Kg Tris (hetero) aryl-pyrazoles and their use
CA2922849A1 (en) 2012-08-31 2014-03-06 Ixchel Pharma, Llc Agents useful for treating obesity, diabetes and related disorders
RU2641916C2 (en) 2012-10-02 2018-01-23 Байер Кропсайенс Аг Heterocyclic compounds as pesticides
WO2014069554A1 (en) * 2012-10-31 2014-05-08 東レ株式会社 Quinuclidine amide derivative and medicinal use of same
CN104994848A (en) 2013-02-22 2015-10-21 默沙东公司 Antidiabetic bicyclic compounds
WO2014139388A1 (en) 2013-03-14 2014-09-18 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
CA2905438A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
CA2905435A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
WO2014174457A1 (en) 2013-04-23 2014-10-30 Council Of Scientific & Industrial Research Pyrazole carboxylic acid analogues as anti-mycobacterial drug candidates
PT3004138T (en) 2013-06-05 2024-06-18 Bausch Health Ireland Ltd Ultra-pure agonists of guanylate cyclase c, method of making and using same
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
JP6657101B2 (en) 2013-11-05 2020-03-04 ベン グリオン ユニバーシティ オブ ザ ネガフ リサーチ アンド ディベロップメント オーソリティ Compounds for the treatment of diabetes and disease complications resulting therefrom
AU2015269247B2 (en) 2014-06-06 2019-10-24 Research Triangle Institute Apelin receptor (APJ) agonists and uses thereof
CA2959208C (en) 2014-08-29 2023-09-19 Tes Pharma S.R.L. Pyrimidine derivatives and their use as inhibitors of alpha-amino-beta-carboxymuconate-epsilon-semialdehyde decarboxylase
CN107405332A (en) 2015-01-06 2017-11-28 艾尼纳制药公司 Treatment and S1P1The method of receptor related illness
CN106279029A (en) * 2015-05-21 2017-01-04 中国人民解放军军事医学科学院毒物药物研究所 4-methyl-1 H-diaryl pyrazole derivatives and the purposes as medicine thereof
CA3002551A1 (en) 2015-06-22 2016-12-29 Arena Pharmaceuticals, Inc. Crystalline l-arginine salt of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid(com pound 1)for use in s1p1 receptor-associated disorders
CN105061315B (en) * 2015-08-06 2017-10-24 大连理工大学 The carboxylic acid compound of one class, 1,5 diphenylpypazole 3 and its application
JP2019501899A (en) 2015-12-09 2019-01-24 リサーチ トライアングル インスティテュート Modified apelin receptor (APJ) agonists and uses thereof
CN108778286A (en) 2016-02-26 2018-11-09 德彪药业国际股份公司 Drug for treating infection in diabetic foot
RU2764039C2 (en) 2016-10-12 2022-01-14 Рисерч Трайэнгл Инститьют Heterocyclic agonists of apelin receptor (apj) and their application
EP3526199B1 (en) 2016-10-14 2022-04-13 Tes Pharma S.r.l. Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase
US11111698B2 (en) 2016-12-05 2021-09-07 Endura Products, Llc Multipoint lock
US11072602B2 (en) 2016-12-06 2021-07-27 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
CN110520124A (en) 2017-02-16 2019-11-29 艾尼纳制药公司 For treating the Compounds and methods for of primary biliary cholangitis
KR101877002B1 (en) * 2017-03-06 2018-07-12 서울대학교 산학협력단 Pharmaceutical composition for prevention and treatment of pruritus comprising pyrazole derivatives and method for screening of the same
TWI805699B (en) 2018-03-01 2023-06-21 日商日本煙草產業股份有限公司 Methyllactam ring compound and pharmaceutical use thereof
WO2019194207A1 (en) 2018-04-04 2019-10-10 日本たばこ産業株式会社 Heteroaryl-substituted pyrazole compound and medicinal use thereof
CA3119509A1 (en) 2018-11-20 2020-05-28 Tes Pharma S.R.L Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxxylase
US11098029B2 (en) 2019-02-13 2021-08-24 Merck Sharp & Dohme Corp. 5-alkyl pyrrolidine orexin receptor agonists
EP4010314B1 (en) 2019-08-08 2024-02-28 Merck Sharp & Dohme LLC Heteroaryl pyrrolidine and piperidine orexin receptor agonists
AU2020417293A1 (en) 2020-01-03 2022-09-01 Berg Llc Polycyclic amides as UBE2K modulators for treating cancer
CA3125847A1 (en) 2020-07-27 2022-01-27 Makscientific, Llc Process for making biologically active compounds and intermediates thereof
US12054480B2 (en) 2020-07-31 2024-08-06 Makscientific, Llc Compounds for treating cannabinoid toxicity and acute cannabinoid overdose
TW202227417A (en) 2020-08-18 2022-07-16 美商默沙東藥廠 Bicycloheptane pyrrolidine orexin receptor agonists

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5132090A (en) * 1989-03-22 1990-09-27 Sterling Drug Inc. Azole-1-alkanamides as antiarrhythmic agents and preparation thereof
AU2358592A (en) * 1991-09-26 1993-04-01 Ortho Pharmaceutical Corporation Regioselective synthesis of 1,5-diarylpyrazole anti-inflammatory agents
AU4324793A (en) * 1992-06-11 1994-01-04 Rhone-Poulenc Agriculture Limited Herbicidal pyrazole-(thio)-carboxamides

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3449350A (en) * 1968-06-24 1969-06-10 Ciba Geigy Corp Certain pyrazole-3-carboxylic acid hydrazide derivatives
ES497143A0 (en) * 1979-11-16 1982-04-01 Morishita Pharma PROCEDURE FOR THE MANUFACTURE OF PYRAZOLE DERIVATIVES
US5164381A (en) * 1986-05-29 1992-11-17 Ortho Pharmaceutical Corporation Pharmacologically active 1,5-diaryl-3-substituted pyrazoles and method for synthesizing the same
US4826868A (en) * 1986-05-29 1989-05-02 Ortho Pharmaceutical Corporation 1,5-Diaryl-3-substituted pyrazoles pharmaceutical compositions and use
US5051518A (en) * 1987-05-29 1991-09-24 Ortho Pharmaceutical Corporation Pharmacologically active 2- and 3-substituted (1',5'-diaryl-3-pyrazolyl)-N-hydroxypropanamides
AU611437B2 (en) * 1987-05-29 1991-06-13 Ortho Pharmaceutical Corporation Pharmacologically active 2- and 3-substituted (1',5'-diaryl-3-pyrazolyl)-n-hydroxypropanamides and method for synthesizing the same
PH27357A (en) * 1989-09-22 1993-06-21 Fujisawa Pharmaceutical Co Pyrazole derivatives and pharmaceutical compositions comprising the same
US5013837A (en) * 1990-03-08 1991-05-07 Sterling Drug Inc. 3-Arylcarbonyl-1H-indole-containing compounds
CA2036307C (en) * 1990-03-08 2002-07-09 Susan Jean Ward 3-arylcarbonyl-1-aminoalkyl-1h-indole-containing antiglaucoma compositions and method
FR2665898B1 (en) * 1990-08-20 1994-03-11 Sanofi DERIVATIVES OF AMIDO-3 PYRAZOLE, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
FR2692575B1 (en) * 1992-06-23 1995-06-30 Sanofi Elf NOVEL PYRAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5132090A (en) * 1989-03-22 1990-09-27 Sterling Drug Inc. Azole-1-alkanamides as antiarrhythmic agents and preparation thereof
AU2358592A (en) * 1991-09-26 1993-04-01 Ortho Pharmaceutical Corporation Regioselective synthesis of 1,5-diarylpyrazole anti-inflammatory agents
AU4324793A (en) * 1992-06-11 1994-01-04 Rhone-Poulenc Agriculture Limited Herbicidal pyrazole-(thio)-carboxamides

Also Published As

Publication number Publication date
HUT64526A (en) 1994-01-28
CA2098944C (en) 1999-09-07
AU4143893A (en) 1994-01-06
NZ247961A (en) 1995-08-28
NO932296L (en) 1993-12-27
IL106099A0 (en) 1993-10-20
SK283399B6 (en) 2003-07-01
RU2119917C1 (en) 1998-10-10
TW494096B (en) 2002-07-11
KR100307050B1 (en) 2001-11-30
FI932891A (en) 1993-12-24
KR940000433A (en) 1994-01-03
IL120517A0 (en) 1997-07-13
MY113022A (en) 2001-11-30
DK0576357T3 (en) 1997-09-15
MX9303664A (en) 1994-01-31
FI113169B (en) 2004-03-15
BR1100409A (en) 1999-10-13
ATE149489T1 (en) 1997-03-15
GR3023535T3 (en) 1997-08-29
JPH0673014A (en) 1994-03-15
EP0576357A1 (en) 1993-12-29
FR2692575B1 (en) 1995-06-30
DE69308395T2 (en) 1997-10-16
FR2692575A1 (en) 1993-12-24
ZA934511B (en) 1994-02-22
UA27728C2 (en) 2000-10-16
NO302819B1 (en) 1998-04-27
HU222577B1 (en) 2003-08-28
HU218797B (en) 2000-12-28
SK65493A3 (en) 1994-02-02
HU9301851D0 (en) 1993-09-28
EP0576357B1 (en) 1997-03-05
CZ117293A3 (en) 1994-03-16
NO932296D0 (en) 1993-06-22
BR9302435A (en) 1994-01-11
CZ289487B6 (en) 2002-02-13
IL106099A (en) 1998-07-15
CA2098944A1 (en) 1993-12-24
DE69308395D1 (en) 1997-04-10
US5624941A (en) 1997-04-29
FI932891A0 (en) 1993-06-22
JP3238801B2 (en) 2001-12-17
ES2101258T3 (en) 1997-07-01

Similar Documents

Publication Publication Date Title
AU664281B2 (en) Novel pyrazole derivatives, method of preparing them and pharamceutical compositions in which they are present
BG103195A (en) Substituted indazole derivatives and their application as inhibitors of phosphodiesterase (pde) type iv and of the production of a tumournecrotic factor (tnf)
UA27238C2 (en) Indoline derivatives, their pharmaceutical acceptable salts which are antagonists of vasopressin vi-receptors, method for their synthesis, intermediate compounds and pharmaceutical composition
CA2263319A1 (en) Quinazoline derivatives and pharmaceutical compositions containing them
CA2242425A1 (en) Quinazoline derivatives as vegf inhibitors
HUP0400684A2 (en) Heterocyclindazole and azaindazole compounds as 5-hydroxytryptamine-6 ligands, their preparation and pharmaceutical compositions containing them
DE69939532D1 (en) GAMMA AMINOBUTTERIC ACID DERIVATIVES, SOLID MEDICAMENTS AND METHOD FOR THE PRODUCTION THEREOF
HUT70206A (en) Aryl or heteroaryl substituted guanidine derivatives, pharmaceutical compositions comprising them and process for producing thereof
CA2258285A1 (en) Substituted indazole derivatives and their use as phosphodiesterase (pde) type iv and tumor necrosis factor (tnf) inhibitors
HUP0401009A2 (en) 1-aryl-or 1-alkylsulfonylbenzole derivatives as 5-hydroxytryptamine-6 ligands, process for their preparation and pharmaceutical compositions containing them
CA2176935A1 (en) Indole-derived azylpiperazines as ligands for 5ht1-like receptors 5ht1b and 5ht1d
ATE148704T1 (en) IMIDAZO (1,2-A&gt;PYRASINE-4-ONE DERIVATIVES WHICH SERVE AS AMPA AND NMDA RECEPTOR ANTAGONISTS
CA2244777A1 (en) 2,3-benzodiazepine derivatives and their use as ampa-receptor inhibitors
NZ512981A (en) Use of pyridazino[4,5-b]indole-1-acetamide derivatives for treating diseases related to the dysfunction of peripheral benzodiazepine receptors
CA2060616A1 (en) Use of 4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine derivatives as free radical scavengers
NO982072D0 (en) Amidine and isothiourea derivatives as inhibitors of nitric oxide synthase
DE69330601D1 (en) SEROTON INERGIC ERGOLIN DERIVATIVES
BG99566A (en) 4-quinoline derivatives with anti helicobacter activity
FR2708604A1 (en) Use of benzenesulphonylindole (phenylsulphonylindole) derivatives for the preparation of medicaments
WO2001021620A3 (en) Amine derivatives of benzo-4,5-thieno-2,3-d pyrimidines
JO1720B1 (en) Hetrocyclic derivatives

Legal Events

Date Code Title Description
HB Alteration of name in register

Free format text: SANOFI-SYNTHELABO